Silo Pharma CEO buys 5,000 company shares in reported trades

Silo Pharma, Inc. Chief Executive Officer and director Eric Weisblum reported purchases of the company’s common stock.

Accepted by SEC EDGAR 12/16/2025 - 06:34 PM EST Learn about SEC filing dates

Rhea-AI Filing Summary

Silo Pharma, Inc. Chief Executive Officer and director Eric Weisblum reported purchases of the company’s common stock. On December 15, 2025, he bought 2,500 shares at $0.41 per share and another 2,500 shares at $0.42 per share. After these transactions, he directly beneficially owned 216,932 shares of Silo Pharma common stock.

Insider Trade Summary

Net Buyer: 5,000 shares

Net Buy 2 txns

Insider Weisblum Eric

Role Chief Executive Officer

Bought 5,000 shs ($2K)

Type	Security	Shares	Price	Value
Purchase	Common Stock	2,500	$0.41	$1K
Purchase	Common Stock	2,500	$0.42	$1K

Holdings After Transaction: Common Stock — 216,932 shares (Direct)

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Silo Pharma (SILO) disclose in this filing?

The filing reports that Eric Weisblum, Silo Pharma’s Chief Executive Officer and director, purchased shares of the company’s common stock.

When did Eric Weisblum buy Silo Pharma (SILO) shares?

Eric Weisblum’s reported stock purchases took place on December 15, 2025.

How many Silo Pharma (SILO) shares did the CEO purchase and at what prices?

He bought 2,500 shares at $0.41 per share and another 2,500 shares at $0.42 per share of Silo Pharma common stock.

What is Eric Weisblum’s role at Silo Pharma (SILO)?

Eric Weisblum is both a Director and an Officer of Silo Pharma, serving as the company’s Chief Executive Officer.

How many Silo Pharma (SILO) shares does Eric Weisblum now beneficially own?

Following the reported transactions, Eric Weisblum directly beneficially owned 216,932 shares of Silo Pharma common stock.

Is this Silo Pharma (SILO) insider report for one or multiple reporting persons?

The document indicates that the form is filed by one reporting person, covering Eric Weisblum’s holdings and transactions.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Weisblum Eric

(Last) (First) (Middle)

C/O SILO PHARMA, INC.

677 N. WASHINGTON BOULEVARD

(Street)

SARASOTA FL 34236

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Silo Pharma, Inc. [ SILO ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Executive Officer

3. Date of Earliest Transaction (Month/Day/Year)
12/15/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	12/15/2025		P		2,500	A	$0.41	214,432	D
Common Stock	12/15/2025		P		2,500	A	$0.42	216,932	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

	/s/ Eric Weisblum	12/16/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.